{"pmid":32213267,"title":"[Interpretation of pathological changes for \"Guidelines for the Diagnosis and Treatment of COVID-19 by the National Health Commission (Trial Version 7)\"].","text":["[Interpretation of pathological changes for \"Guidelines for the Diagnosis and Treatment of COVID-19 by the National Health Commission (Trial Version 7)\"].","Zhonghua Bing Li Xue Za Zhi","Ding, Y Q","Bian, X W","32213267"],"journal":"Zhonghua Bing Li Xue Za Zhi","authors":["Ding, Y Q","Bian, X W"],"date":"2020-03-28T11:00:00Z","year":2020,"_id":"32213267","week":"202013|Mar 23 - Mar 29","doi":"10.3760/cma.j.cn112151-20200318-00221","source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1662445896439169024,"score":7.208847,"similar":[{"pmid":32033513,"title":"[Interpretation of \"Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial Version 5)\"].","text":["[Interpretation of \"Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial Version 5)\"].","the National Health Commission of the People's Republic of China publish the guidelines for the diagnosis and treatment of novel coronavirus (2019-nCoV) infection (trial version 5) .With the awareness and understanding of the disease, the guidelines have been revised for recognize, treat, and prevent diseases. Then, what are the contents of the fifth edition of the guide issued updated compared to the fourth edition, now, learn together.","Zhonghua Yi Xue Za Zhi","Lin, L","Li, T S","32033513"],"abstract":["the National Health Commission of the People's Republic of China publish the guidelines for the diagnosis and treatment of novel coronavirus (2019-nCoV) infection (trial version 5) .With the awareness and understanding of the disease, the guidelines have been revised for recognize, treat, and prevent diseases. Then, what are the contents of the fifth edition of the guide issued updated compared to the fourth edition, now, learn together."],"journal":"Zhonghua Yi Xue Za Zhi","authors":["Lin, L","Li, T S"],"date":"2020-02-09T11:00:00Z","year":2020,"_id":"32033513","week":"20206|Feb 03 - Feb 09","doi":"10.3760/cma.j.issn.0376-2491.2020.0001","keywords":["2019 Novel coronavirus","guidelines","pneumonia"],"source":"PubMed","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1662334544563404800,"score":161.96976},{"pmid":32209888,"title":"Diagnosis and Treatment Plan for COVID-19 (Trial Version 6).","text":["Diagnosis and Treatment Plan for COVID-19 (Trial Version 6).","Chin Med J (Engl)","32209888"],"journal":"Chin Med J (Engl)","date":"2020-03-27T11:00:00Z","year":2020,"_id":"32209888","week":"202013|Mar 23 - Mar 29","doi":"10.1097/CM9.0000000000000819","source":"PubMed","topics":["Diagnosis","Treatment"],"weight":1,"_version_":1662444220179283970,"score":86.41297},{"pmid":32051073,"title":"[Recommendation for the diagnosis and treatment of novel coronavirus infection in children in Hubei (Trial version 1)].","text":["[Recommendation for the diagnosis and treatment of novel coronavirus infection in children in Hubei (Trial version 1)].","Since December 2019, a cluster of patients have been diagnosed to be infected with 2019 novel coronavirus (2019-nCoV) in Wuhan, China. The epidemic has been spreading to other areas of the country and abroad. A few cases have progressed rapidly to acute respiratory distress syndrome and/or multiple organ function failure. The epidemiological survey has indicated that the general population is susceptible to 2019-nCoV. A total of 14 children (6 months to 14 years of age, including 5 cases in Wuhan) have been confirmed to be infected with 2019-nCoV in China so far. In order to further standardize and enhance the clinical management of 2019-nCoV infection in children, reduce the incidence, and decrease the number of severe cases, we have formulated this diagnosis and treatment recommendation according to the recent information at home and abroad.","Zhongguo Dang Dai Er Ke Za Zhi","32051073"],"abstract":["Since December 2019, a cluster of patients have been diagnosed to be infected with 2019 novel coronavirus (2019-nCoV) in Wuhan, China. The epidemic has been spreading to other areas of the country and abroad. A few cases have progressed rapidly to acute respiratory distress syndrome and/or multiple organ function failure. The epidemiological survey has indicated that the general population is susceptible to 2019-nCoV. A total of 14 children (6 months to 14 years of age, including 5 cases in Wuhan) have been confirmed to be infected with 2019-nCoV in China so far. In order to further standardize and enhance the clinical management of 2019-nCoV infection in children, reduce the incidence, and decrease the number of severe cases, we have formulated this diagnosis and treatment recommendation according to the recent information at home and abroad."],"journal":"Zhongguo Dang Dai Er Ke Za Zhi","date":"2020-02-14T11:00:00Z","year":2020,"_id":"32051073","week":"20207|Feb 10 - Feb 16","source":"PubMed","locations":["Hubei","China","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1662334544508878848,"score":74.648125},{"pmid":32029004,"pmcid":"PMC7003341","title":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version).","text":["A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version).","In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named \"2019 novel coronavirus (2019-nCoV)\" by the World Health Organization (WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world's attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development; we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control (including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV.","Mil Med Res","Jin, Ying-Hui","Cai, Lin","Cheng, Zhen-Shun","Cheng, Hong","Deng, Tong","Fan, Yi-Pin","Fang, Cheng","Huang, Di","Huang, Lu-Qi","Huang, Qiao","Han, Yong","Hu, Bo","Hu, Fen","Li, Bing-Hui","Li, Yi-Rong","Liang, Ke","Lin, Li-Kai","Luo, Li-Sha","Ma, Jing","Ma, Lin-Lu","Peng, Zhi-Yong","Pan, Yun-Bao","Pan, Zhen-Yu","Ren, Xue-Qun","Sun, Hui-Min","Wang, Ying","Wang, Yun-Yun","Weng, Hong","Wei, Chao-Jie","Wu, Dong-Fang","Xia, Jian","Xiong, Yong","Xu, Hai-Bo","Yao, Xiao-Mei","Yuan, Yu-Feng","Ye, Tai-Sheng","Zhang, Xiao-Chun","Zhang, Ying-Wen","Zhang, Yin-Gao","Zhang, Hua-Min","Zhao, Yan","Zhao, Ming-Juan","Zi, Hao","Zeng, Xian-Tao","Wang, Yong-Yan","Wang, Xing-Huan","32029004"],"abstract":["In December 2019, a new type viral pneumonia cases occurred in Wuhan, Hubei Province; and then named \"2019 novel coronavirus (2019-nCoV)\" by the World Health Organization (WHO) on 12 January 2020. For it is a never been experienced respiratory disease before and with infection ability widely and quickly, it attracted the world's attention but without treatment and control manual. For the request from frontline clinicians and public health professionals of 2019-nCoV infected pneumonia management, an evidence-based guideline urgently needs to be developed. Therefore, we drafted this guideline according to the rapid advice guidelines methodology and general rules of WHO guideline development; we also added the first-hand management data of Zhongnan Hospital of Wuhan University. This guideline includes the guideline methodology, epidemiological characteristics, disease screening and population prevention, diagnosis, treatment and control (including traditional Chinese Medicine), nosocomial infection prevention and control, and disease nursing of the 2019-nCoV. Moreover, we also provide a whole process of a successful treatment case of the severe 2019-nCoV infected pneumonia and experience and lessons of hospital rescue for 2019-nCoV infections. This rapid advice guideline is suitable for the first frontline doctors and nurses, managers of hospitals and healthcare sections, community residents, public health persons, relevant researchers, and all person who are interested in the 2019-nCoV."],"journal":"Mil Med Res","authors":["Jin, Ying-Hui","Cai, Lin","Cheng, Zhen-Shun","Cheng, Hong","Deng, Tong","Fan, Yi-Pin","Fang, Cheng","Huang, Di","Huang, Lu-Qi","Huang, Qiao","Han, Yong","Hu, Bo","Hu, Fen","Li, Bing-Hui","Li, Yi-Rong","Liang, Ke","Lin, Li-Kai","Luo, Li-Sha","Ma, Jing","Ma, Lin-Lu","Peng, Zhi-Yong","Pan, Yun-Bao","Pan, Zhen-Yu","Ren, Xue-Qun","Sun, Hui-Min","Wang, Ying","Wang, Yun-Yun","Weng, Hong","Wei, Chao-Jie","Wu, Dong-Fang","Xia, Jian","Xiong, Yong","Xu, Hai-Bo","Yao, Xiao-Mei","Yuan, Yu-Feng","Ye, Tai-Sheng","Zhang, Xiao-Chun","Zhang, Ying-Wen","Zhang, Yin-Gao","Zhang, Hua-Min","Zhao, Yan","Zhao, Ming-Juan","Zi, Hao","Zeng, Xian-Tao","Wang, Yong-Yan","Wang, Xing-Huan"],"date":"2020-02-08T11:00:00Z","year":2020,"_id":"32029004","week":"20206|Feb 03 - Feb 09","doi":"10.1186/s40779-020-0233-6","keywords":["*2019 novel coronavirus","*2019-nCoV","*Clinical practice guideline","*Evidence-based medicine","*Infectious diseases","*Pneumonia","*Rapid advice guideline","*Respiratory disease"],"source":"PubMed","locations":["Hubei","Chinese","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis","Prevention","Mechanism"],"weight":1,"_version_":1662334544579133440,"score":70.94436},{"pmid":32125132,"title":"[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].","text":["[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].","The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs.","Zhonghua Jie He He Hu Xi Za Zhi","32125132"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","date":"2020-03-04T11:00:00Z","year":2020,"_id":"32125132","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn112147-20200221-00138","keywords":["Advanced non-small cell lung cancer","COVID-19","Management"],"source":"PubMed","locations":["optimal"],"topics":["Treatment","Diagnosis","Prevention"],"weight":1,"_version_":1662334544051699712,"score":53.431957}]}